March 12, 2021
Roche and Chugai Pharmaceutical said on March 11 that their Actemra (tocilizumab) in combination with Gilead Sciences’ Veklury (remdesivir) failed to meet the primary endpoint in a global PIII study for the treatment of severe COVID-19 pneumonia. Chugai, which is...read more